Suggested remit - To appraise the clinical and cost effectiveness of nivolumab with ipilimumab within its marketing authorisation for untreated recurrent or metastatic squamous cell cancer of the head and neck
 
Status Proposed
Process STA 2018
ID number 1429

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
07 June 2019 - 05 July 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance